PMID- 18677380
OWN - NLM
STAT- MEDLINE
DCOM- 20100615
LR  - 20220311
IS  - 1671-167X (Print)
IS  - 1671-167X (Linking)
VI  - 40
IP  - 4
DP  - 2008 Aug 18
TI  - [Application of the in situ hybridization with EWS dual-color break-apart 
      fluorescence probe and anti-CD99 and anti-FLI-1 antibodies in the diagnosis of 
      Ewing's sarcoma/primitive neuroectodermal tumor].
PG  - 358-62
AB  - OBJECTIVE: To investigate the value of using EWS dual-color, break-apart 
      rearrangement probe fluorescence in situ hybridization (FISH) technique, CD99 and 
      FLI-1 antibodies immunohistochemistry in the diagnosis of Ewing's 
      sarcoma/primitive neuroectodermal tumor (EWS/PNET). METHODS: Thirty-five cases of 
      EWS/PNET and 24 cases of non-EWS/PNET small round cell tumor were analyzed by 
      FISH and immunohistochemically detected with FLI-1 and CD99 antibodies. 
      Comparison between FISH and immunohistochemical results was carried out and their 
      diagnostic value was evaluated. RESULTS: The sensitivity, specificity, positive 
      predictive value and negative predictive value of FISH in EWS/PNET were 
      93.8%(30/32), 81.8%(18/22), 88.2%(30/34) and 90%(18/20); those of CD99 were 
      100%(35/35), 58.3% (14/24), 77.8%(35/45) and 100%(14/14); those of FLI-1 were 
      71.4%(25/35), 62.5%(15/24), 73.5%(25/34), 60%(15/25), respectively. The 
      sensitivity, specificity, positive predictive value and negative predictive value 
      of combined use of CD99 and FLI-1 were 71.4%(25/35), 75%(18/24), 80.6%(25/31) and 
      64.3%(18/28), those of combined use of FLI-1 and FISH were 68.7%(22/32), 
      86.4%(19/22), 88%(22/25) and 65.5%(19/29), those of combined use of CD99 and FISH 
      were 93.7%(30/32), 95.5%(21/22), 96.8%(30/31) and 91.3%(21/23), respectively. 
      CONCLUSION: EWS dual-color, break-apart rearrangement probe FISH is a highly 
      sensitive and specific technique in the diagnosis of EWS/PNET. The combination of 
      CD99 and FISH is the method of choice for the diagnosis of EWS/PNET. The 
      combination of CD99 and FLI-1 can improve the specificity in EWS/PNET without the 
      data of FISH.
FAU - Liu, Bao-yue
AU  - Liu BY
AD  - Department of Pathology, Peking University School of Basic Medical Sciences, 
      Beijing, China.
FAU - Yang, Yu
AU  - Yang Y
FAU - DU, Juan
AU  - DU J
FAU - Zhang, Yan
AU  - Zhang Y
FAU - Wang, Hua
AU  - Wang H
FAU - Zheng, Jie
AU  - Zheng J
LA  - chi
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - China
TA  - Beijing Da Xue Xue Bao Yi Xue Ban
JT  - Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health 
      sciences
JID - 101125284
RN  - 0 (12E7 Antigen)
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Neoplasm)
RN  - 0 (Antigens, CD)
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (CD99 protein, human)
RN  - 0 (Cell Adhesion Molecules)
RN  - 0 (FLII protein, human)
RN  - 0 (Microfilament Proteins)
RN  - 0 (RNA-Binding Protein EWS)
RN  - 0 (Receptors, Cytoplasmic and Nuclear)
RN  - 0 (Trans-Activators)
SB  - IM
MH  - 12E7 Antigen
MH  - Antibodies, Monoclonal/immunology
MH  - Antibodies, Neoplasm/immunology
MH  - Antigens, CD/*immunology
MH  - Biomarkers, Tumor/analysis/genetics
MH  - Bone Neoplasms/*diagnosis/genetics/immunology
MH  - Cell Adhesion Molecules/*immunology
MH  - Humans
MH  - In Situ Hybridization, Fluorescence/methods
MH  - Microfilament Proteins/*immunology
MH  - Neuroectodermal Tumors, Primitive, Peripheral/*diagnosis/genetics/immunology
MH  - Predictive Value of Tests
MH  - RNA-Binding Protein EWS/*immunology
MH  - Receptors, Cytoplasmic and Nuclear/*immunology
MH  - Sarcoma, Ewing/*diagnosis/genetics/immunology
MH  - Sensitivity and Specificity
MH  - Trans-Activators
EDAT- 2008/08/05 09:00
MHDA- 2010/06/16 06:00
CRDT- 2008/08/05 09:00
PHST- 2008/08/05 09:00 [pubmed]
PHST- 2010/06/16 06:00 [medline]
PHST- 2008/08/05 09:00 [entrez]
PST - ppublish
SO  - Beijing Da Xue Xue Bao Yi Xue Ban. 2008 Aug 18;40(4):358-62.